"Oxymorphone" - Books

Result Filters

Results: 1 to 20 of 75 books (263 items)

<< First< Prev

Page of 4

Next >Last >>

Select item 49688741.

Opioid Treatments for Chronic Pain [Internet].

Chou R, Hartung D, Turner J, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. (Comparative Effectiveness Review, No. 229.)

Top results in this book Table of Contents

Select item 29652982.

The Clinical Effectiveness and Cost-Effectiveness of Management Strategies for Sciatica: Systematic Review and Economic Model.

Lewis R, Williams N, Matar HE, et al.

Southampton (UK): NIHR Journals Library; 2011 Nov. (Health Technology Assessment, No. 15.39.)

Top results in this book Table of Contents

Select item 51876383.

Opioids for pain relief after caesarean birth: Caesarean birth: Evidence review F.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2021 Mar. (NICE Guideline, No. 192.)

Top results in this book Table of Contents

Select item 44036684.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2026 Jan-.

Top results in this book Table of Contents

Select item 57704205.

Veterans, Prescription Opioids and Benzodiazepines, and Mortality, 2007–2019: Three Target Trial Emulations.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Evaluating the Effects of Opioids and Benzodiazepines on All-Cause Mortality in Veterans; Doebler DA, Strom BL, editors.

Washington (DC): National Academies Press (US); 2025 Mar 27.

Top results in this book Table of Contents

Select item 26591826.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 48538167.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 52797188.

Evidence reviews for sepsis: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review M.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2019 Mar. (NICE Guideline, No. 121.)

Top results in this book Table of Contents

Select item 52779729.

Evidence reviews for heart disease: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review C.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2019 Mar. (NICE Guideline, No. 121.)

Top results in this book Table of Contents

Select item 527778210.

Evidence reviews for asthma: Intrapartum care for women with existing medical conditions or obstetric complications and their babies: Evidence review D.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2019 Mar. (NICE Guideline, No. 121.)

Top results in this book Table of Contents

Select item 509190811.

Evidence review for pharmacological management of sciatica: Low back pain and sciatica in over 16s: assessment and management: Evidence review A.

National Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2020 Sep. (NICE Guideline, No. 59.)

Top results in this book Table of Contents

Select item 543074612.

Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Reports [Internet].

Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul-.

Top results in this book Table of Contents

Select item 483801813.

Clinical Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.

Top results in this book Table of Contents

Select item 526582814.

Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families: Updated 2021 [Internet].

Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2018. (Treatment Improvement Protocol (TIP) Series, No. 63.)

Top results in this book Table of Contents

Select item 475942815.

Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 456572816.

Drugs and Lactation Database (LactMed®) [Internet].

Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Top results in this book Table of Contents

Select item 282062217.

Medical Genetics Summaries [Internet].

Pratt VM, Scott SA, Pirmohamed M, et al., editors.

Bethesda (MD): National Center for Biotechnology Information (US); 2012-.

Top results in this book Table of Contents

Select item 445440018.

Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Phillips JK, Ford MA, Bonnie RJ, editors.

Washington (DC): National Academies Press (US); 2017 Jul 13.

Top results in this book Table of Contents

Select item 422515619.

Noninvasive Treatments for Low Back Pain [Internet].

Chou R, Deyo R, Friedly J, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Feb. (Comparative Effectiveness Reviews, No. 169.)

Top results in this book Table of Contents

Select item 327563820.

Recognition and Alleviation of Pain and Distress in Laboratory Animals.

National Research Council (US) Committee on Pain and Distress in Laboratory Animals.

Washington (DC): National Academies Press (US); 1992.

Top results in this book Table of Contents

<< First< Prev

Page of 4

Next >Last >>

Supplemental Content

Images search in Bookshelf

FIGURE 1-1Nationally estimated number of prescriptions dispensed for extended-release/long-acting (ER/LA) and selected immediate-release (IR) opioid analgesics (oral solids and transdermal products) from U.S. outpatient retail pharmacies, 2005–2015

*ER/LA opioid molecules include buprenorphine transdermal patch, fentanyl transdermal patch, hydrocodone ER, hydromorphone ER, morphine ER, oxycodone ER, oxymorphone ER, tapentadol ER, and methadone (all approved and marketed ER/LAs at the time). IR opioid molecules include hydrocodone IR combination analgesics (hydrocodone in combination with acetaminophen, ibuprofen, or aspirin), oxycodone IR combination analgesics (oxycodone in combination with acetaminophen, ibuprofen, or aspirin), oxycodone IR, hydromorphone IR, morphine IR, tapentadol IR, and oxymorphone IR. Buprenorphine indicated for medication-assisted treatment is not included.
SOURCE: Staffa, 2017.

Introduction.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Phillips JK, Ford MA, Bonnie RJ, editors. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC): National Academies Press (US); 2017 Jul 13.
Figure 5Network Diagram of Trial Withdrawal Rate Network Meta-Analysis

BUP = buprenorphine; FENT = fentanyl; HYD = hydromorphone; MET = methadone; MOR = morphine; OXM = oxymorphone; OXN = oxycodone-naloxone; OXY = oxycodone; TAP = tapentadol; TRA = tramadol.
Source: Figure S1c of Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-Analysis by Meng Z, Yu J, Acuff M, Luo C, Wang S, Yu L, and Huang R⁹³ is licensed under https://creativecommons.org/licenses/by/4.0/.

Summary of Indirect Comparisons.

Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
Figure 4Network Diagram of the Incidence of Adverse Events Network Meta-Analysis

BUP = buprenorphine; FENT = fentanyl; HYD = hydromorphone; MOR = morphine; OXM = oxymorphone; OXN = oxycodone-naloxone; OXY = oxycodone; TAP = tapentadol; TRA = tramadol.
Source: Figure S1a of Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-Analysis by Meng Z, Yu J, Acuff M, Luo C, Wang S, Yu L, and Huang R⁹³ is licensed under https://creativecommons.org/licenses/by/4.0/.

Summary of Indirect Comparisons.

Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
Figure 9Drug overdose deaths involving natural and semisynthetic opioids per 100,000 population, by age and ethnicity, 2020

Note: Natural opioid includes morphine and codeine; semisynthetic opioid includes drugs such as oxycodone, hydrocodone, hydromorphone, and oxymorphone. Rates are crude rates and are not age adjusted. Drug overdose deaths are identified using underlying cause-of-death codes from the 10^th revision of the International Classification of Diseases (ICD-10-CM). Deaths involving natural and semisynthetic opioids use codes T40.2.

SUBSTANCE USE DISORDERS.

2022 National Healthcare Quality and Disparities Report [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Oct.